Envisagenics and Boehringer Ingelheim inked a multi-target, option-style collaboration valued at up to $1 billion-plus, centered on Envisagenics’ alternative RNA splicing SpliceCore platform. Boehringer will fund research to validate tumor-specific targets derived from splice events, with an option to license selected targets once programs conclude. The arrangement aims to expand the therapeutic modality menu for tumor-selective targets, spanning antibodies and multispecific formats, while offering Envisagenics non-dilutive funding to support its pipeline. The deal also reinforces the expanding use of transcriptome-based target discovery in solid tumors. Envisagenics framed the pact as financial flexibility while validating SpliceCore’s output for partner translation, putting tumor-specific splicing biology at the center of the next wave of precision oncology negotiations.